Research Topics
Genomes and Genes
| A JakubowskaSummaryAffiliation: University of Szczecin Country: Poland Publications
| Collaborators
|
Detail Information
Publications
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska
Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
Br J Cancer 106:2016-24. 2012..Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase (MTHFR), both of which are important either directly or indirectly in maintaining genomic integrity...
BRCA2 gene mutations in families with aggregations of breast and stomach cancersA Jakubowska
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Sczcecin, Poland
Br J Cancer 87:888-91. 2002....
Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphismAnna Jakubowska
Pomeranian Medical University, Department of Genetics and Pathology, ul Polabska 4, 70 115 Szczecin, Poland
BMC Cancer 8:90. 2008..The C to T transition in the 3' untranslated region of the prohibitin (PHB) gene alters mRNA function and has recently been shown to be associated with hereditary breast cancer risk in Polish women harbouring BRCA1 mutations...
BARD1 and breast cancer in PolandAnna Jakubowska
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Breast Cancer Res Treat 107:119-22. 2008..To investigate whether or not a genetic variant in BARD1 (Cys557Ser) contributes to early-onset breast cancer in Poland, or modifies the risk of breast cancer in women with an inherited predisposition to breast cancer...
The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriersAnna Jakubowska
Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 70 115 Szczecin, Poland
Cancer Epidemiol Biomarkers Prev 16:270-5. 2007..In conclusion, the RAD51 C allele seems to protect against both breast and ovarian cancer in women harboring BRCA1 mutations...
Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?Anna Jakubowska
International Hereditary Cancer Centre IHCC, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
Eur J Cancer 45:837-42. 2009..The PHB 1630 C/T single nucleotide polymorphism was associated with breast cancers with clinical features typical for BRCA1-positive tumours and is deserving of further study...
Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in PolandAnna Jakubowska
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin 70 115, Poland
Cancer Epidemiol Biomarkers Prev 12:457-9. 2003..07-0.62; P = 0.0015). This finding suggests that RAD51 is a genetic modifier of breast cancer risk in BRCA1 carriers in the Polish population. It will be of interest to confirm this in other populations as well...
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriersAnna Jakubowska
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Polabska 4, 70 115 Szczecin, Poland
Breast Cancer Res Treat 121:639-49. 2010..89-1.32). The polymorphism was not associated with breast cancer risk for either BRCA1 or BRCA2 mutation carriers. The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers...
A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancerAnna Jakubowska
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
Eur J Hum Genet 11:955-8. 2003..It is expected that the penetrance of BRCA2 mutations for stomach cancer will vary from country to country, reflecting local environmental and lifestyle factors...
CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in PolandAnna Jakubowska
International Hereditary Cancer Centre, Department of Genetics and Pathology, Pomeranian Medical University, ul Połabska 4, 70 115 Szczecin, Poland
Fam Cancer 9:605-8. 2010..CDH1 gene mutations are not present in Polish families with HDGC defined by the modified clinical criteria. Further studies of families with HDGC matching the restrictive criteria for HDGC are needed...
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancerC Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Połabska 4, 70 115 Szczecin, Poland
J Med Genet 43:863-6. 2006..Recently, a large deletion of exons 9 and 10 of CHEK2 was identified in several unrelated patients with breast cancer of Czech or Slovak origin. The geographical and ethnic extent of this founder allele has not yet been determined...
Detection of germline mutations in the BRCA1 gene by RNA-based sequencingA Jakubowska
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Polabska, Poland
Hum Mutat 18:149-56. 2001..The sensitivity of our analyses was sufficient to reliably detect mutations without the necessity of tissue culturing to obtain enough template cDNA for analysis...
Breast cancer predisposing alleles in PolandB Gorski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Polabska 4, Szczecin, Poland 70 115
Breast Cancer Res Treat 92:19-24. 2005..1) than for the missense mutation I157T (OR=1.4). This study suggests that cancer risks may be specific for particular alleles of a susceptibility gene and that these different risks should be taken into account by genetic counselors...
Comparison of Alu-PCR, microsatelite instability, and immunohistochemical analyses in finding features characteristic for hereditary nonpolyposis colorectal cancerT Debniak
Department of Genetics and Pathology, Pomeranian Medical University, Poland
J Cancer Res Clin Oncol 127:565-9. 2001....
Common variants of DNA repair genes and malignant melanomaT Debniak
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Eur J Cancer 44:110-4. 2008..In conclusion, we report an increased melanoma risk among carriers of the N991D change of the BRCA2 and no association of the CHEK2 changes with malignant melanoma...
Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutationsC Cybulski
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, ul Połabska 4, Szczecin, Poland
J Med Genet 46:132-5. 2009..However, it is of interest to estimate the breast cancer risks associated with carrying two mutations because this information may be informative for genetic counsellors and may provide clues to the carcinogenic process...
Estrogen receptor status in CHEK2-positive breast cancers: implications for chemopreventionC Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Clin Genet 75:72-8. 2009..01). Women with a CHEK2 mutation face a fourfold increase in the risk of ER-positive breast cancer and might be candidates for tamoxifen chemoprevention...
An inherited NBN mutation is associated with poor prognosis prostate cancerC Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Połabska 4, Szczecin 70 115, Poland
Br J Cancer 108:461-8. 2013..To establish the contribution of eight founder alleles in three DNA damage repair genes (BRCA1, CHEK2 and NBS1) to prostate cancer in Poland, and to measure the impact of these variants on survival among patients...
Fhit protein expression in hereditary and sporadic colorectal cancersP Hadaczek
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin
Pol J Pathol 52:125-32. 2001..Our results suggest that the FHIT gene plays an important role in carcinogenesis of at least one fourth of all colorectal cancers...
Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2J Menkiszak
Clinic of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
Eur J Gynaecol Oncol 25:99-100. 2004..The purpose of the present study was to identify the clinical and pathologic features of ovarian cancers in patients who have a family history of breast or ovarian cancer but who do not have a mutation in the BRCA1 or BRCA2 gene...
Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic StatesG Kurzawski
Hereditary Cancer Centre, Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
J Med Genet 39:E65. 2002
Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skinTadeusz Debniak
Department of Genetics, Pomeranian Academy of Medicine, Szczecin 70 111, Poland
Melanoma Res 13:365-70. 2003..It seems that the 657del5 mutation of exon 6 of NBS1 gene may be responsible for the occurrence of a small proportion of MM patients, characterized by the occurrence of breast cancer among their relatives...
Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in PolandJ Menkiszak
Clinic of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
Eur J Gynaecol Oncol 25:93-5. 2004..In conclusion, preventive oophorectomy is acceptable to most Polish women at high risk of hereditary ovarian cancer and should be among the range of services offered in cancer genetics clinics...
The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutationAnna Jakubowska
Department of Genetics and Pathology, Pomeranian Medical University, ul Polabska 4, 70 115 Szczecin, Poland
Breast Cancer Res Treat 104:67-74. 2007..Breast cancer risk did not differ between carriers of the 300 T > G and 5382insC mutation. Our results suggest that the PHB 3'UTR T allele increases the risk of breast cancer in patients who are already at increased risk of disease...
Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregationT Debniak
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin 70 111, Al Powst Wlkp 72, Poland
Eur J Cancer Prev 12:241-5. 2003..In conclusion, it seems to be justified to consider systematic breast surveillance beginning at the age around 35-40 years as an option in women from < or =55 MM/CFA families...
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancerB Gorski
Department of Genetics and Pathology, Hereditary Cancer Center, 70 115 Szczecin, Poland
Am J Hum Genet 66:1963-8. 2000..In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities-5382insC, C61G, and 4153delA-accounted for 51%, 20%, and 11% of the identified mutations, respectively...
Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL geneC Cybulski
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
J Med Genet 39:E38. 2002
Breast cancer susceptibility genesJan Lubinski
Pomeranian Medical University, Department of Genetics and Pathology, International Hereditary Cancer Center, Szczecin, Poland
J BUON 12:S23-9. 2007..We are presenting it on examples of late-onset breast cancers from Poland, but it seems to be justified to expect that similar results can be achieved from other malignancies...
Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risksAnna Jakubowska
Pomeranian Medical University, ul Polabska 4, 70 111, Szczecin, Poland
Breast Cancer Res Treat 104:299-308. 2007..Together, it appears that functional polymorphisms in the MTHFR gene modify the risk of breast and may potentially alter the risk of ovarian cancer in women with an inherited predisposition...
Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study)G Kurzawski
International Hereditary Cancer Center Department of Genetics and Pathology, Universit of Szczecin and Pomeranian Medical University, Szczecin, Poland
Clin Genet 69:40-7. 2006....
The rs1447295 and DG8S737 markers on chromosome 8q24 and cancer risk in the Polish populationDominika Wokołorczyk
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, ul Polabska 4, Szczecin 70 115, Poland
Eur J Cancer Prev 19:167-71. 2010..Although the carcinogenic mechanism associated with this particular locus of 8q24 is unclear it appears to be specific to prostate cancer...
Epistatic relationship between the cancer susceptibility genes CHEK2 and p27Cezary Cybulski
Pomeranian Medical University, Szczecin, Poland
Cancer Epidemiol Biomarkers Prev 16:572-6. 2007..Two-gene models provide numerous challenges for gene identification and cancer risk assessment...
NBS1 is a prostate cancer susceptibility geneC Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Polabska 4, 70 115 Szczecin, Poland
Cancer Res 64:1215-9. 2004....
BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphismsAnna Jakubowska
Pomeranian Medical University, Szczecin, Poland
Breast Cancer Res Treat 119:201-11. 2010..Thus, it appears that these polymorphisms do not influence disease risk in Polish women carrying one of the three common BRCA1 founder mutations...
Ovarian cancer of endometrioid type as part of the MSH6gene mutation phenotypeJanina Suchy
Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Academy of Medicine, ul Polabska 4, Szczecin 70 115, Poland
J Hum Genet 47:529-31. 2002..Our results and reports by others indicate that, besides colorectal and endometrial cancer, the late-onset endometrioid type of ovarian cancer can be a feature of families with MSH6 germline mutations...
Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genesA Jakubowska
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Polabska, Poland
Hum Mutat 17:52-60. 2001..DNA sequencing using RNA as a basis for template construction may be a valuable and economical alternative to genomic DNA sequencing...
CDKN2A-positive breast cancers in young women from PolandTadeusz Debniak
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Połabska 4, Szczecin, Poland
Breast Cancer Res Treat 103:355-9. 2007..To investigate the contribution of CDKN2A A148T common variant to early-onset breast cancer in Poland, and to establish the characteristic features of these cancers...
Hereditary ovarian cancer in PolandJanusz Menkiszak
Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
Int J Cancer 106:942-5. 2003..It is important that mutation surveys be conducted in other countries prior to the introduction of national genetic screening programs...
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutationsJanusz Menkiszak
Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
J Appl Genet 45:255-63. 2004..We concluded that cystadenoma is likely to be a characteristic feature of the subgroup of families with hereditary ovarian cancers unassociated with BRCA1/BRCA2 constitutional mutations...
Novel RB1 gene constitutional mutations found in Polish patients with familial and/or bilateral retinoblastomaA Jakubowska
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
Hum Mutat 18:459. 2001..Constitutional mutations were found in five out of eight patients. Three mutations were novel: g.IVS7+5G>A, g.156709T>A, and g.IVS21+1G>A (p.G203-E240del, p.Y659X, and p.I703-E737del)...
CYP1B1 and predisposition to breast cancer in PolandJoanna Matyjasik
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Breast Cancer Res Treat 106:383-8. 2007..The CYP1B1 gene is a polymorphic member of the P450 gene family and is considered to be a candidate gene for cancers of various types...
Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in PolandTadeusz Debniak
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Polabska 4, 70 115 Szczecin, Poland
Eur J Cancer Prev 17:389-91. 2008..The results of this study revealed a paucity of mutations in CDKN2A/ARF suggesting that in the Polish population this gene does not contribute significantly to early-onset breast cancer, pancreatic cancer and malignant melanoma...
The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple OrgansJan Lubinski
Pomeranian Medical University, Szczecin, Poland
Hered Cancer Clin Pract 3:59-63. 2005..3% of individuals) and may be responsible for an important fraction of cancer cases. We estimate that the lifetime cancer risk among carriers of this allele is 30% higher than that of individuals with two wild-type alleles...
Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomasCezary Cybulski
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
Hered Cancer Clin Pract 2:93-7. 2004..We were able to obtain blood samples from 19 of mutation positive cases. Eight (42%) of these harboured germline mutations in persons from distinct undiagnosed VHL families...
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in PolandCezary Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Połabska 4, 70 115 Szczecin, Poland
Breast Cancer Res Treat 102:119-22. 2007..This is one of the most common protein-truncating CHEK2 variants in Poland. Overall, 2% of all breast cancers in Poland can be attributed to one of three protein-truncating mutations in CHEK2...
Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathologyJan Lubinski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Polabska 4, 70 115, Szczecin, Poland
Breast Cancer Res Treat 114:121-6. 2009..Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67...
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancersCezary Cybulski
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, ul Połabska 4, 70 115 Szczecin, Poland
Carcinogenesis 29:762-5. 2008..g. p53 mutations) and have a high level of genotoxic DNA damage induced by tobacco smoke. We speculate that lung cancer cells with impaired CHEK2 function undergo increased rates of cell death...
BRCA1 mutations and prostate cancer in PolandCezary Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Poland
Eur J Cancer Prev 17:62-6. 2008..1-11.3; P=0.045); in particular for familial prostate cancer (odds ratio=12; 95% confidence interval: 2.9-51; P=0.0004). We consider that the risk of prostate cancer in BRCA1 carriers varies with the position of the mutation...
CHEK2 mutations and HNPCC-related colorectal cancerJanina Suchy
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, il Połabska 4, Szczecin, Poland
Int J Cancer 126:3005-9. 2010..5; p < 0.0001). We conclude that the I157T variant of CHEK2 increases the risk of colorectal cancer among MMR-negative, HNPCC/HNPCC-related families in Poland...
A high proportion of founder BRCA1 mutations in Polish breast cancer familiesBohdan Gorski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Int J Cancer 110:683-6. 2004..This rapid test will facilitate large-scale national epidemiologic and clinical studies of hereditary breast cancer, potentially including studies of chemoprevention...
The NOD2 3020insC mutation and the risk of colorectal cancerGrzegorz Kurzawski
International Hereditary Cancer Center, Department of Genetics and Pathology, Szczecin, Poland
Cancer Res 64:1604-6. 2004..23; P = 0.0046). The results indicate that NOD2 may be a predisposing factor to colorectal cancer characterized by an older average age of disease onset in persons who do not harbor any other genetic predisposition to disease...
Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridizationJacek Gronwald
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Połabska 4, 70 115 Szczecin, Poland
Int J Cancer 114:230-6. 2005..These findings need confirmation by more extensive studies because only a limited number of cases were analysed and there are relatively few reports published...
CHEK2-positive breast cancers in young Polish womenCezary Cybulski
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
Clin Cancer Res 12:4832-5. 2006..To investigate the contribution of CHEK2 mutations to early-onset breast cancer in Poland and to establish the characteristic features of these cancers...
Germline 657del5 mutation in the NBS1 gene in breast cancer patientsBohdan Gorski
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin 70 111, Al Powst Wlkp 72, Poland
Int J Cancer 106:379-81. 2003..It appears that the 657del5 mutation in exon 6 of the NBS1 gene is responsible for the occurrence of a small but significant proportion of familial breast cancer patients...
Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancersBohdan Gorski
Department of Genetics and Pathology, Pomeranian Medical University, ul Połabska 4, Szczecin 70 115, Poland
J Appl Genet 44:419-23. 2003..Among 14 families without BRCA1 Polish founder mutations in this gene were excluded in 2 families and BRCA2 mutation was excluded in one family...
A range of cancers is associated with the rs6983267 marker on chromosome 8Dominika Wokolorczyk
International Hereditary Cancer Center, Department of Genetics and Pathology and Clinic of Urology, Pomeranian Medical University, Szczecin, Poland
Cancer Res 68:9982-6. 2008..Our results suggest that the range of cancers associated with the rs6983267 marker might be larger than previously thought...
Pleomorphic adenoma of salivary glands does not appear to be a BRCA-1-dependent tumour in a Polish cohortJakub Lubinski
Department of Otolaryngology with Laryngological Oncology, Pomeranian Medical University, Szczecin, Poland
Anticancer Res 28:3011-3. 2008..The aim of the study was to examine whether pleomorphic adenoma of salivary glands can occur on the basis of constitutional BRCA-1 mutations...
Molecular basis of inherited predispositions for tumorsJan Lubinski
Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
Acta Biochim Pol 49:571-81. 2002....
DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in PolandCezary Cybulski
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
Urol Int 79:44-9. 2007..We investigated whether or not inherited variation in MSR1, RNASEL and E-cadherin contribute to prostate cancer risk in Poland...
Fine needle aspiration biopsy and molecular analysis in differential diagnosis of lymphoproliferative diseases of the orbit and eye adnexaEwa Wolska-Szmidt
Department of Ophtalmology, Pomeranian Medical University, Szczecin
Pol J Pathol 55:51-7. 2004..Clonality studies by PCR may be performed in material obtained through FNAB. Clonality assessment by PCR technique is very useful in differential diagnosis of lymphoproliferative disordes...
The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish womenAnna Jakubowska
Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
Cancer Lett 262:71-6. 2008..63, 95% CI, 0.48-0.83), and a potential effect on ovarian cancer risk (OR(adj) 0.62, 95% CI, 0.33-1.18; OR(clustered) 0.62, 95% CI, 0.47-0.83). Thus, the 936_C>T polymorphism appears to modify disease risks in BRCA1 carriers...
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer riskAnna Jakubowska
J Med Genet 44:408-11. 2007..Thus, it appears that the ITGB3_Leu33Pro polymorphism may potentially increase the risk of ovarian cancer in Polish women with an inherited BRCA1 mutation...
Clinical characteristics of hereditary ovarian cancer (HOC) in PolandJanusz Menkiszak
Dept. of Genetics and Pathology Pomeranian Medical Academy
Ginekol Pol 73:733-9. 2002..CONCLUSIONS: Clinical features of HOC in Poland and in other countries are similar. 2. Introduction of DNA tests to the clinical and pedigree diagnostic criteria allows detection of subgroups of HOC with different clinical features...
[Characteristics of selected features of hereditary ovarian cancer in carriers of constitutional BRCA1 gene mutation]Janusz Menkiszak
Ginekol Pol 73:1084-9. 2002..38. CONCLUSIONS: 1. Features of HOC in studied material and in other populations are similar 2. High morphological grading is the most characteristic for HOC in BRCA1 carriers...
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 studyFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers...
German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancerMuhammad U Rashid
Division of Molecular Genome Analysis, German Cancer Research Center, B055, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
Eur J Cancer 41:2896-903. 2005..In patients with a high-risk profile however, CHEK2*1100delC was indicative for this risk and highest for early-onset breast cancer...
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studiesAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
Am J Hum Genet 81:1186-200. 2007..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers...
Lower airway papillomatosis in childrenLidia Zawadzka-Głos
Department of Paediatric Otorhinolaryngology, The Medical University of Warsaw, 24 Marszałkowska Str, 00 576 Warsaw, Poland
Int J Pediatr Otorhinolaryngol 67:1117-21. 2003..In differential diagnosis of these changes in the lungs we should take into consideration the presence of papilloma in the bronchi. A prognosis of papillomatosis in the lower airways in children is always serious...
[Plant receptor kinases]Anna Jakubowska
Zakład Biochemii, Instytut Biologii Ogólnej i Molekularnej, Uniwersytet Mikołaja Kopemika, ul Gagarina 9, 87 100 Torun
Postepy Biochem 53:133-42. 2007..Despite knowledge of RLKs functions is increasing rapidly, yet major challenges remain. These include identifying ligands that activate RLKs and characterizing downstream pathways...
